20 articles
Novel liposome therapy delivers miR-10a to atherosclerotic plaques, reprogramming inflammatory macrophages and reducing disease progression in mice.
Scientists discover how to enhance cancer immunotherapy by converting tumor-supporting immune cells into tumor-fighting ones.
A phase 1 trial tests RBD7022, a novel subcutaneous RNA-based therapy, for safety and dosing in adults with high LDL cholesterol.
CRISPR gene therapy shows promise for curing genetic heart diseases like high cholesterol and amyloidosis with one-time treatments.
Amgen's siRNA therapy olpasiran targets lipoprotein(a), a stubborn cardiovascular risk factor with no approved treatments.
CAR-M2 therapy successfully reversed kidney scarring in lab studies by eliminating harmful endothelial cells and promoting healing.
Experimental drug enlicitide matches injectable therapies' power but in convenient pill form, potentially transforming heart disease prevention.
A new analysis shows olezarsen reduces apoC-III by up to 75% across chylomicrons, HDL, LDL/VLDL, and Lp(a) in familial chylomicronemia syndrome.
New study shows clearing senescent cells with Navitoclax improves heart function and reduces inflammation in heart failure with preserved ejection fraction.
Revolutionary nanobody drug targets two proteins simultaneously, achieving complete tumor elimination in preclinical studies.
A forward genetic screen in mice reveals HELZ2 helicase degrades APOB mRNA, linking RNA stability to fatty liver disease and heart disease risk.
Breakthrough siRNA therapy dramatically reduces lipoprotein(a), a stubborn cardiovascular risk factor resistant to statins and lifestyle changes.
The first disease-specific treatment for Barth syndrome gains FDA accelerated approval, targeting mitochondrial dysfunction to restore muscle strength.
Scientists discover targeting two cellular pathways simultaneously could overcome treatment resistance in neuroendocrine tumors.
Sotatercept emerges as potential treatment for combined pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction.
SHR-1918 antibody dramatically reduced LDL cholesterol in patients with severe genetic hypercholesterolemia through novel pathway.
Researchers created synthetic immune receptors that boost macrophages' ability to clear cellular debris, reducing inflammation in liver and heart disease.
Clinical trial tests whether cardiac shockwave therapy can improve heart function when combined with bypass surgery.
Advanced cholesterol-lowering therapies show promise for dramatically reducing cardiovascular disease risk through innovative approaches.
Breakthrough anti-fibril depleters could revolutionize treatment for transthyretin amyloid cardiomyopathy, a deadly heart condition.
